MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Glutathione Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Glutathione is the endogenous tripeptide gamma-L-glutamyl-L-cysteinyl-glycine that serves as the principal intracellular antioxidant and redox buffer in human cells, with hepatic concentrations of 5 to 10 mM. It directly scavenges reactive oxygen and nitrogen species, regenerates oxidized vitamin C and vitamin E, conjugates xenobiotics via glutathione S-transferases for phase II detoxification, and supports lymphocyte function and mitochondrial integrity. People study IV, IM, and inhaled glutathione for skin lightening (via tyrosinase inhibition and a pheomelanin shift), Parkinson's disease, NAFLD, oxidative stress, and post-chemotherapy support [PMID: 28301006][PMID: 22311878]. Oral bioavailability is poor because of gastrointestinal hydrolysis, and IV glutathione has a circulating half-life of only about 10 minutes, requiring frequent administration. No glutathione product is FDA-approved for skin lightening, and the FDA has issued warnings about IV glutathione injections compounded for cosmetic use.
Reconstitute: Add 2 mL bacteriostatic water → 300 mg/mL concentration.
Easy measuring: At 300 mg/mL, 1 unit = 0.01 mL = 3 mg (3000 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
FDA warning on IV cosmetic use: The Philippine FDA in 2011 and the US FDA in subsequent advisories warned that IV glutathione for skin lightening is unapproved and has been linked to thyroid dysfunction, Stevens-Johnson syndrome, and kidney injury at high doses.
Oral bioavailability is poor: Standard oral glutathione is largely hydrolyzed to its constituent amino acids. Liposomal and S-acetyl-glutathione formulations show modestly better plasma elevations, but NAC supplementation remains the more evidence-backed strategy for raising intracellular GSH.
Skin-lightening mechanism: Glutathione inhibits tyrosinase and shifts melanogenesis from dark eumelanin toward lighter pheomelanin. Effect sizes for lightening in controlled trials are modest, slow, and reverse on discontinuation.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[17].
Interactive Glutathione Syringe Calculator
Currently visualizing the 600 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 600mg dry powder in 2mL water yields 300.00 mg/mL. To evaluate a 250mcg dose, pull to 0.1 units (0 syringe ticks).
U-100 Syringe Representation
0.1 Units (0 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mg | 33 units (0.33 mL) |
| Weeks 3–4 | 150 mg | 50 units (0.50 mL) |
| Weeks 5–8 | 200 mg | 67 units (0.67 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 600 mg vial.
Peptide Vials (Glutathione, 600 mg each):
- check4 weeks (100–150 mg/day avg) ≈ 3 vials
- check8 weeks (150–200 mg/day avg) ≈ 7 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check4 weeks: 28 syringes
- check8 weeks: 56 syringes
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.
- check4 weeks (3 vials): 6 mL → 1 × 10 mL bottle
- check8 weeks (7 vials): 14 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check4 weeks: 56 swabs → recommend 1 × 100-count box
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
Mechanism of Action (MOA)
Glutathione (γ-L-glutamyl-L-cysteinyl-glycine, GSH) is a low-molecular-weight tripeptide containing an unusual γ-linkage between glutamate and cysteine that resists most peptidases. It is synthesized in the cytosol of essentially all mammalian cells through two ATP-dependent steps catalyzed by glutamate-cysteine ligase (the rate-limiting enzyme) and glutathione synthetase. Intracellular GSH concentrations range from 1 to 10 mM, making it the most abundant intracellular thiol. The cysteine sulfhydryl group is the chemically reactive moiety that mediates virtually all of GSH's biological functions [1]. GSH performs four major roles. First, as a direct antioxidant, GSH reduces hydrogen peroxide and lipid hydroperoxides through the action of glutathione peroxidase, becoming oxidized to GSSG (glutathione disulfide) which is then reduced back to GSH by glutathione reductase using NADPH supplied by the pentose phosphate pathway. The GSH/GSSG ratio (typically >100:1 in healthy cells) is a fundamental indicator of cellular redox status. Second, GSH conjugates electrophilic xenobiotics through glutathione-S-transferase enzymes in Phase II hepatic detoxification, producing water-soluble mercapturic acids that are excreted in urine and bile. This pathway is the principal mechanism for detoxifying acetaminophen-derived NAPQI, environmental toxins, and chemotherapy agents [2]. Third, GSH regenerates other antioxidants, particularly ascorbate (vitamin C) and α-tocopherol (vitamin E), maintaining the cellular antioxidant network. Fourth, GSH maintains protein thiol redox status through glutathionylation, a reversible post-translational modification that regulates the activity of numerous enzymes, transcription factors, and ion channels. Tissue GSH levels decline with age, in chronic illness, and after exposure to oxidative stressors including alcohol, acetaminophen overdose, ultraviolet light, ionizing radiation, and many chemotherapy drugs. Reduced GSH levels are observed in non-alcoholic fatty liver disease, Parkinson's disease, schizophrenia, HIV infection, sickle cell disease, chronic obstructive pulmonary disease, and aging. Restoring GSH levels has been investigated as a therapeutic strategy in many of these conditions, with mixed results. Direct intravenous administration of reduced glutathione bypasses the gastrointestinal barrier and produces transient plasma concentrations dramatically higher than physiological levels, although plasma GSH is cleared rapidly with a half-life of approximately fifteen minutes, primarily through hepatic and renal extraction. The extent to which exogenous GSH crosses cell membranes to elevate intracellular concentrations is debated; cells generally synthesize GSH de novo from precursor amino acids (cysteine being the rate-limiting substrate) rather than importing intact GSH [2]. Clinically, intravenous glutathione is administered at doses ranging from 600 mg to 2400 mg per session, diluted in saline and infused over fifteen to thirty minutes, typically one to three times weekly for four to eight weeks depending on indication. Common applications include hepatic support in non-alcoholic fatty liver disease and drug-induced liver injury (where IV GSH reduces serum ALT and AST), adjunctive Parkinson's disease therapy, cosmetic skin lightening (controversial and based on indirect effects on tyrosinase and pheomelanin/eumelanin balance), and oxidative stress reduction in chronic illness. Intramuscular administration at 600 mg per dose is used when IV access is impractical. Liposomal and reduced-form oral preparations achieve modest increases in plasma GSH but the magnitude is far below that produced by IV administration. Glutathione is not FDA-approved for any condition in the United States but is widely compounded and used off-label in clinical practice [3].
Clinical Trial Efficacy Highlights
- starA systematic review and meta-analysis in Frontiers in Medicine (2023) summarized clinical evidence that intravenous glutathione reduces serum ALT and AST in patients with non-alcoholic fatty liver disease and drug-induced liver injury, supporting its role as adjunctive hepatic support, although effects on hard outcomes such as fibrosis progression or mortality have not been demonstrated in large randomized trials [3].
- starPre-clinical and small clinical studies indicate that intravenous glutathione may transiently improve motor function in Parkinson's disease, but a double-blind placebo-controlled trial by Mischley and colleagues did not demonstrate sustained clinical benefit over placebo, suggesting that intermittent dosing may be insufficient to durably correct nigrostriatal oxidative stress [4].
- starGlutathione is the antidote for acetaminophen toxicity in the form of its precursor N-acetylcysteine (NAC), which is FDA-approved for this indication and acts by replenishing hepatic GSH consumed in detoxifying the reactive metabolite NAPQI, providing the most robust clinical evidence for GSH-based interventions in oxidative liver injury [2].
- starTopical and intravenous glutathione have been promoted for skin lightening based on inhibition of tyrosinase and a shift from eumelanin to pheomelanin synthesis; small studies report modest skin tone improvements, but the FDA and Philippine FDA have warned against high-dose IV GSH for cosmetic skin lightening due to safety concerns and lack of formal approval [1].
- starOral glutathione bioavailability is low because intestinal γ-glutamyl transpeptidase hydrolyzes the peptide; however, liposomal oral preparations and reduced-form GSH tablets have demonstrated modest increases in plasma and erythrocyte GSH in small trials, with corresponding improvements in oxidative stress markers in patients with chronic disease [2].
- starIntranasal glutathione has been investigated in Parkinson's disease and other neurodegenerative conditions on the rationale of bypassing the blood-brain barrier; small open-label studies report symptomatic improvement, but rigorous controlled trials are lacking and the FDA has not approved any intranasal glutathione product [4].
- starSafety profiling indicates that IV glutathione is generally well tolerated at standard doses, with rare reports of bronchospasm in asthmatic patients, Stevens-Johnson syndrome, hypotension, and anaphylactoid reactions; high-dose chronic IV use for cosmetic purposes carries an unclear safety profile and has been associated with significant adverse events in unregulated settings [3].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningIntravenous glutathione is generally well tolerated, but rare cases of bronchospasm, particularly in asthmatic patients, have been reported and the infusion should be administered slowly and discontinued at the first sign of respiratory symptoms.
- warningAnaphylactoid reactions, hypotension, flushing, and rash have been documented with IV glutathione; Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in unregulated cosmetic skin-lightening protocols using high-dose IV GSH.
- warningIntramuscular administration can produce injection-site pain, induration, and rarely sterile abscess; intranasal use can cause local irritation and rhinorrhea.
- warningOral GSH is generally well tolerated; mild gastrointestinal upset, flatulence, and a transient sulfur taste or odor (from cysteine release) are the most common complaints.
- warningSulfite hypersensitivity may be relevant because some IV glutathione formulations contain sulfite preservatives; asthmatic patients should be evaluated for sulfite sensitivity before treatment.
- warningUse during pregnancy and lactation has not been adequately studied; while endogenous GSH is essential during pregnancy, supplemental dosing should be discussed with a clinician.
- warningSkin lightening protocols using high-dose IV GSH have been associated with thyroid dysfunction, kidney injury, embolism, and serious cutaneous reactions in unregulated settings and are explicitly discouraged by major regulatory authorities.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical glutathione dosage?expand_more
Intravenous glutathione is typically administered at 600–2400 mg per session, infused over 15–30 minutes, 1–3 times weekly for 4–8 weeks. Intramuscular dosing uses 600 mg per session. Oral liposomal GSH is commonly used at 250–1000 mg daily. There are no FDA-approved dosing recommendations.
How is glutathione administered?expand_more
Glutathione is administered intravenously (most common in clinical use), intramuscularly, intranasally (research), topically, or orally as liposomal or reduced-form preparations. IV administration produces the highest plasma concentrations but requires sterile technique and medical supervision.
Can glutathione be combined with other compounds?expand_more
Glutathione is commonly combined in IV protocols with vitamin C, alpha-lipoic acid, and B vitamins for synergistic antioxidant effects. Oral GSH may be paired with NAC (cysteine precursor), selenium, and milk thistle. Avoid simultaneous mixing in IV bags with high-dose vitamin C without compounding guidance.
What are the side effects of glutathione?expand_more
IV GSH is generally well tolerated. Rare adverse effects include bronchospasm in asthmatic patients, anaphylactoid reactions, hypotension, and rash. High-dose IV use for skin lightening has been associated with serious cutaneous and systemic reactions in unregulated settings.
Is glutathione FDA approved?expand_more
No. Glutathione is not FDA-approved for any therapeutic indication in the United States. It is available as a dietary supplement orally and is widely compounded for injection and infusion by licensed compounding pharmacies. The FDA has warned against IV glutathione for cosmetic skin lightening.
Academic References & Study Citations
Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489-492. View Scientific Paper →
Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30(1-2):1-12. View Scientific Paper →
Honda Y, Kessoku T, Sumida Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot prospective clinical trial. BMC Gastroenterol. 2017;17(1):96. View Scientific Paper →
Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb study of intranasal glutathione in Parkinson's disease. J Parkinsons Dis. 2017;7(2):289-299. View Scientific Paper →
Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17(9):827-833. View Scientific Paper →
Sinha R, Sinha I, Calcagnotto A, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr. 2018;72(1):105-111. View Scientific Paper →
Pizzorno J. Glutathione! Integr Med (Encinitas). 2014;13(1):8-12. View Scientific Paper →
Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal. 2009;11(11):2685-2700. View Scientific Paper →
Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(7):1159-1170. View Scientific Paper →